Aerosil as a novel co-crystal co-former for improving the dissolution rate of hydrochlorothiazide
Co-crystallization of drugs with benign co-formers is promising for enhancing dissolution
rate of poorly soluble drugs. The selection of safe and pharmacologically inert co-formers is …
rate of poorly soluble drugs. The selection of safe and pharmacologically inert co-formers is …
Pharmaceutical cocrystal: an antique and multifaceted approach
PS Panzade, GR Shendarkar - Current drug delivery, 2017 - ingentaconnect.com
Background: Pharmaceutical cocrystal is an emerging approach to tailor physicochemical
and mechanical properties of drug substances. Cocrystals are composed of API and …
and mechanical properties of drug substances. Cocrystals are composed of API and …
Solubility modelling and solvent effect for domperidone in twelve green solvents
M Zheng, J Chen, G Chen, A Farajtabar… - Journal of Molecular …, 2018 - Elsevier
Solid solubility is a significant physical property for a drug development and design. In the
present work, the domperidone solubility, which has less study in the near-term, was …
present work, the domperidone solubility, which has less study in the near-term, was …
[HTML][HTML] Formulation and evaluation of fast dissolving tablet containing domperidone ternary solid dispersion
DM Patel, SP Patel, CN Patel - International journal of …, 2014 - ncbi.nlm.nih.gov
Materials and Methods: Binary and ternary solid dispersions were prepared by fusion
method. They were characterized by solubility study, in vitro dissolution, dissolution …
method. They were characterized by solubility study, in vitro dissolution, dissolution …
Encapsulation of a citrus by-product extract: Development, characterization and stability studies of a nutraceutical with antioxidant and metalloproteinases inhibitory …
MR Lauro, L Crasci, C Carbone, RP Aquino… - LWT-Food Science and …, 2015 - Elsevier
Spray-dried aqueous extract from citrus by-product (“pastazzo”, ExO) was studied to
evaluate the polyphenols content, the antioxidant properties and the inhibition of …
evaluate the polyphenols content, the antioxidant properties and the inhibition of …
Dual-purpose vardenafil hydrochloride/dapoxetine hydrochloride orodispersible tablets: in vitro formulation/evaluation, stability study and in vivo comparative …
K El-Refai, MH Teaima… - Drug development and …, 2018 - Taylor & Francis
Erectile dysfunction (ED) is the most important disorder after premature ejaculation for
sexual activity in men. Vardenafil hydrochloride (VH) is an oral therapy for the treatment of …
sexual activity in men. Vardenafil hydrochloride (VH) is an oral therapy for the treatment of …
[HTML][HTML] Enhancing the low oral bioavailability of sulpiride via fast orally disintegrating tablets: formulation, optimization and in vivo characterization
Sulpiride (SUL) is a dopamine D2-receptor antagonist used for management of GIT
disturbance and it has anti-psychotic activities based on the administered dose. SUL …
disturbance and it has anti-psychotic activities based on the administered dose. SUL …
[HTML][HTML] Enhancement of the oral bioavailability of fexofenadine hydrochloride via Cremophor® El-Based liquisolid tablets
SA Yehia, MS El-Ridi, MI Tadros… - Advanced …, 2015 - ncbi.nlm.nih.gov
Purpose: The current work aimed to develop promising Fexofenadine hydrochloride (FXD)
liquisolid tablets able to increase its oral bioavailability and shorten time to reach maximum …
liquisolid tablets able to increase its oral bioavailability and shorten time to reach maximum …
[PDF][PDF] Solubility enhancement of gliclazide by solid dispersion method
SD More, SB Sontakke - Asian J Pharm Clin Res, 2013 - Citeseer
In the present research work, an attempt was made to improve the solubility and dissolution
rate of a poorly soluble drug, Gliclazide by solid dispersion method using soluplus and …
rate of a poorly soluble drug, Gliclazide by solid dispersion method using soluplus and …
Combining acetyl salicylic acid and rofecoxib into novel oral tablets normalize platelet function with potential higher tolerability in patients with cardiovascular …
Rofecoxib (ROF), a potent selective COX-II inhibitor NSAID, has been withdrawn from the
market due to its high risk on patients with cardiovascular disorders (CVD). In the current …
market due to its high risk on patients with cardiovascular disorders (CVD). In the current …